Spinocerebellar Ataxia type 3 is rare in the Peruvian Population

Mario Cornejo-Olivas (mario.cornejo.o@incngen.org.pe)
Instituto Nacional de Ciencias Neurológicas

Lesly Solis-Ponce
Instituto Nacional de Ciencias Neurológicas

Ismael Araujo-Aliaga
Instituto Nacional de Ciencias Neurológicas

Karina Milla-Neyra
Instituto Nacional de Ciencias Neurológicas

Olimpio Ortega
Instituto Nacional de Ciencias Neurológicas

Maryenela Illanes-Manrique
Instituto Nacional de Ciencias Neurológicas

Pilar Mazzetti
Instituto Nacional de Ciencias Neurológicas

Carla Manrique-Enciso
Instituto Nacional de Ciencias Neurológicas

Diana Cubas-Montecino
Instituto Nacional de Ciencias Neurológicas

Maria Luiza Saraiva-Pereira
Hospital de Clínicas de Porto Alegre

Laura B. Jardim
Hospital de Clínicas de Porto Alegre

Elison Sarapura-Castro
Instituto Nacional de Ciencias Neurológicas

Research Article

Keywords: Allelic distribution, ATXN3, Machado-Joseph Disease, Peruvian ataxic patients, MJD/SCA3 phenotype, Spinocerebellar ataxia type 3

Posted Date: September 23rd, 2022

DOI: https://doi.org/10.21203/rs.3.rs-2069341/v1
Abstract

Spinocerebellar ataxia type 3 or Machado-Joseph Disease (MJD/SCA3) is the most prevalent autosomal dominant cerebellar ataxia worldwide, but its frequency varies by geographic region. We describe MJD/SCA3 patients diagnosed in a tertiary healthcare institution in Peru. In a cohort of 341 individuals with clinical ataxia diagnosis, seven MJD/SCA3 probands were identified and their pedigrees extended, detecting a total of 18(5%) MJD/SCA3 cases. Out of 682 alleles from this cohort, the 23-CAG repeat was the most common \textit{ATXN3} allele (32.1%), followed by the 14-CAG repeat allele (26%). Normal alleles ranged from 12 to 38 repeats while pathogenic alleles ranged from 61-75 repeats. We identified 101 large normal (LN) alleles (14.8%). Five out of seven families declared an affected family member traced back to foreign countries (England, Japan, China, and Trinidad and Tobago). MJD/SCA3 patients showed ataxia, accompanied by pyramidal signs, dysarthria and dysphagia as well as abnormal oculomotor movements. In conclusion, \textit{ATXN3} allelic distribution in non-MJD/SCA3 patients with ataxia is similar to the distribution in normal individuals around the world, whereas LN allele frequency reinforces no correlation with the frequency of MJD/SCA3. Evidence of an abnormal MJD/SCA3 phenotype was not found. Further haplotypes are required to confirm the foreign origin of MJD/SCA3 in the Peruvian population.

Introduction

Spinocerebellar ataxia type 3 or Machado-Joseph Disease (MJD/SCA3) is a late-onset autosomal dominant neurodegenerative disease associated with abnormal expansion of the CAG microsatellite within the \textit{ATXN3} gene (14q32.1) [1]. MJD/SCA3 shows marked phenotypic variability: from pure ataxic forms associated with other signs such as neuropathies or parkinsonism, to forms with severe spasticity and dystonia [2]. The symptoms have traditionally been classified into differential clinical types or subphenotypes including cerebellar ataxia, pyramidal signs, extrapyramidal signs -dystonia and parkinsonism-, peripheral neuropathy, spastic paraplegia and opthamoplegia [3;4]. Non-motor symptoms such as autonomic dysfunction, fatigue, pain, neuropsychiatric, and sleep disorders have also been described [5].

MJD/SCA3 is considered the most common dominant inherited ataxia worldwide with a variable frequency depending on the geographic region [6]. The relative frequency of MJD/SCA3 among dominant ataxias is highest in Brazil (59.6%) [7] and Portugal (57.8%) [8], whereas countries such as Italy (1.1%) [9] and South Africa (3.7%) [10] have reported lower relative frequencies. About Latin America, it is well known that Brazil has the highest frequency of MJD/SCA3, although the information about other countries is still limited. Venezuela also has a considerable relative frequency of 25% [11], followed by Chile (20%) [12]; Argentina (20%) [13]; Mexico (12%) [14] and Cuba (1.2%) [15].

In Peru, there are anecdotal reports on MJD/SCA3 cases [16], suggesting a low frequency of this type of ataxia in this country. The main purposes of this study are to analyze the frequency of MJD/SCA3 within...
ataxic patients in Peru, and to describe phenotype and \textit{ATXN3} allelic distribution within the Peruvian MJD/SCA3 population.

**Materials And Methods**

**Study Design and population**

We conducted a cross-sectional study to describe the clinical and molecular characteristics of MJD/SCA3 patients with extended pedigrees, as well as to explore the allelic distribution of \textit{ATXN3}-[CAG\(_{(n)}\)] within a cohort of ataxic patients screened for MJD/SCA3 at a neurogenetics outpatient clinic in Lima, Peru. From January 1996 to February 2022, a total of 341 individuals from both genders with clinical diagnosis of hereditary ataxia followed up at a tertiary hospital were included in this study. The exclusion criteria were (a) the presence of any abnormality on the following tests at recruitment that explained the occurrence of ataxia or related neurological symptoms: basic blood biochemistry; vitamin B12, Vitamin E, VDRL (venereal disease research laboratory), chest X-ray; abdominal ultrasound; mammary ultrasound and mammography (in women); thyroid-stimulating hormone, lymphocyte and thrombocyte count, hemoglobin, erythrocyte mean corpuscular volume, sedimentation rate, v, antibodies (anti-HIV, Human Immunodeficiency Virus), qualitative urine test, anti-Yo and anti-Hu antibodies; (b) suggestive MRI for a vascular, autoimmune, or infectious process in the central nervous system. Informed consent was obtained from each participant. This study was approved by the Institutional Review Board from the Instituto Nacional de Ciencias Neurologicas, Lima, Peru.

**\textit{ATXN3} Genotyping**

Blood samples were collected, and then DNA was isolated from leukocytes at the Neurogenetics Lab in Lima using standard procedures [17]. DNA samples underwent \textit{ATXN3} genotyping based on the amplification of the CAG repeat within \textit{ATXN3} by Polymerase Chain Reaction (PCR) employing a modified procedure originally standardized by Kawaguchi et al., 1994 [18]. The modified PCR protocol had the following conditions: 1X PCR buffer, 10% DMSO, 1.5 mM MgCl\(_2\), 0.15 mM of each dNTPs, 1 \textmu M of each primer (MJD52 5'-CCAGTGACTACTTTGATTCG-3' and MJD25 5'- TGGCCTTTCACATGGATGTGAA-3'), 0.5 U of Platinum Taq DNA Polymerase and 0.3 ng of DNA genomic in a final reaction volume of 10 \textmu L. The amplification program had the following initial conditions: 2 min of initial denaturation at 94°C; 28 cycles of 30 sec denaturation at 94°C, 30 sec hybridization at 58.5°C and 1 min extension at 72°C; and 10 min of final extension at 72°C The amplicons were observed by 6% non-denaturing polyacrylamide gel electrophoresis. Allele sizing was performed using reference samples of known genotype analyzed by PCR and capillary electrophoresis through Rede Neurogenetica-Brazil.

Samples not displaying both alleles were further genotyped by Triple Repeat-PCR (TP-PCR) followed by 10% non-denaturing polyacrylamide gel electrophoresis. The TP-PCR was performed employing a modified procedure originally standardized by Melo et al., 2016 [19]. The modified TP-PCR protocol had the following conditions: 1X PCR buffer, 6% DMSO, 1.5 mM MgCl\(_2\), 0.2 mM of each dNTPs, 0.3 \textmu M of
primer MJD25R (5'-TGGCCTTTCACATGGATGTGA-3'), 0.06 µM of primer ForIntRep (5'-TACGCATCCAGTTTGAGACG-3') and 0.3 µM of primer ForTail (5'-TACGCATCCAGTTTGAGACGCAGCAGCAGCAGCAGCAG-3') 0.4 U of Platinum Taq DNA Polymerase and 10 ng of DNA genomic in a final reaction volume of 10 µL. The amplification program had the following initial conditions: 2 min of initial denaturation at 94°C; 30 cycles of 30 sec denaturation at 94°C, 30 sec hybridization at 62°C and 45 sec extension at 72°C; and 10 min of final extension at 72°C.

Due to the lack of consensus to date, we classified ATXN3 alleles according to Saute & Jardim et al., 2015 [20]. 12 to 44 CAG repeat length alleles are considered normal and ≥51 CAG repeats as pathogenic. Within normal alleles, we identified a subgroup of large normal (LN) alleles with ≥27 CAG repeats [21].

**MJD/SCA3 extended families identification and data collection**

Among the 341 participants with ataxic symptoms, we identified seven non-related MJD/SCA3 probands. We extended the pedigrees of all seven probands and contacted most of the affected family members. We performed home visits to a total of 18 affected individuals by home visits in four different cities across the country to complete a standardized clinical questionnaire, neurological examination, SARA, MoCA and PHQ-9 rating scales assessment. Extended pedigrees were drawn using an online pedigree tool (https://www.progenygenetics.com). Age at onset was defined when the patient or a close relative noticed the first symptom of the disease, which was usually but not always gait ataxia. We collected information on the presence or absence of several neurological findings, as well as clinical and family history.

**Statistical analysis**

We estimated ATNX3 allelic frequencies and presented their distributions in vertical bars, grouped according to classification mentioned above. We calculated the mean, median and mode of the allelic frequency.

**Results**

**Identified MJD/SCA3 pedigrees**

We found 18 MJD/SCA3 affected individuals (six women) from seven different families.

The mean age at sample drawing/recruitment was 59.7 ±12.6 years (range 40 to 77 years). Expanded pedigrees showed five out of seven SCA3/MJD3 families declare a foreign origin (figure 1). The age at onset ranged from 20 years to 64 years, with an average of 46.3±13.3 years. The mean duration of disease was 14.3 ±10.6 years and the mean time at definitive diagnosis was 12.8 ±10.8 years. There was no predominance regarding paternal transmission (50%). The mean SARA score was 12.2±7.1 (n=16) and mean NESSCA score was 11.8 ±4.9 (n=15). Cognitive performance was screened by the MoCA, where the mean score was 18.9 ±4.3 points (n=11) and anxiety/depression by PHQ-9, with a mean score of 10.1±5.8 points (n=11). Main demographic and genetics findings are summarized in a table (Table 1) and
clinical findings were plotted by frequency (Figure 2). For additional individua-based clinical findings, see the supplementary data (Table S1).

Table 1. Main demographic and genetics findings

<table>
<thead>
<tr>
<th>Family</th>
<th>Individual</th>
<th>Age at recruitment (yrs)</th>
<th>Age at onset(years)</th>
<th>Age at last follow-up</th>
<th>Time for diagnosis (years)</th>
<th>ATXN3- (CAG)n</th>
<th>Family history</th>
<th>Type of transmission</th>
<th>SARA</th>
<th>NA</th>
<th>SSCA</th>
<th>MoCA</th>
<th>PHQ-9</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCA3-001</td>
<td>1.1</td>
<td>48, female</td>
<td>33</td>
<td>50</td>
<td>14</td>
<td>87/23</td>
<td>Yes</td>
<td>Maternal</td>
<td>19.5</td>
<td>20</td>
<td>24</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>SCA3-002</td>
<td>1.2</td>
<td>70, female</td>
<td>52</td>
<td>70</td>
<td>39</td>
<td>65/27</td>
<td>Yes</td>
<td>Maternal</td>
<td>19</td>
<td>14</td>
<td>13</td>
<td>18</td>
<td></td>
</tr>
<tr>
<td>SCA3-003</td>
<td>2.1</td>
<td>66, male</td>
<td>55</td>
<td>68</td>
<td>14</td>
<td>60/27</td>
<td>Yes</td>
<td>Maternal</td>
<td>21</td>
<td>15</td>
<td>15</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>SCA3-004</td>
<td>2.2</td>
<td>45, male</td>
<td>20</td>
<td>NA</td>
<td>33</td>
<td>79/14</td>
<td>Yes</td>
<td>Paternal</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>SCA3-005</td>
<td>2.3</td>
<td>53, male</td>
<td>50</td>
<td>NA</td>
<td>55</td>
<td>74/14</td>
<td>Yes</td>
<td>Paternal</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>SCA3-006</td>
<td>3.1</td>
<td>83, female</td>
<td>NA</td>
<td>6</td>
<td>67/27</td>
<td>Yes</td>
<td>Maternal</td>
<td>8.5</td>
<td>5</td>
<td>25</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SCA3-007</td>
<td>3.2</td>
<td>74, male</td>
<td>89</td>
<td>NA</td>
<td>15</td>
<td>61/28</td>
<td>Yes</td>
<td>Maternal</td>
<td>19</td>
<td>17</td>
<td>13</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>SCA-003</td>
<td>3.3</td>
<td>79, male</td>
<td>48</td>
<td>NA</td>
<td>29</td>
<td>89/22</td>
<td>Yes</td>
<td>Paternal</td>
<td>19</td>
<td>17</td>
<td>13</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>SCA-004</td>
<td>3.4</td>
<td>48, female</td>
<td>43</td>
<td>NA</td>
<td>2</td>
<td>89/22</td>
<td>Yes</td>
<td>Paternal</td>
<td>19</td>
<td>17</td>
<td>13</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>SCA-005</td>
<td>3.5</td>
<td>51, male</td>
<td>48</td>
<td>NA</td>
<td>4</td>
<td>89/22</td>
<td>Yes</td>
<td>Paternal</td>
<td>19</td>
<td>17</td>
<td>13</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>SCA-006</td>
<td>3.6</td>
<td>43, male</td>
<td>38</td>
<td>NA</td>
<td>4</td>
<td>87/23</td>
<td>Yes</td>
<td>Paternal</td>
<td>19</td>
<td>17</td>
<td>13</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>SCA-007</td>
<td>3.7</td>
<td>77, male</td>
<td>63</td>
<td>NA</td>
<td>15</td>
<td>84/14</td>
<td>Yes</td>
<td>Paternal</td>
<td>19</td>
<td>17</td>
<td>13</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>SCA-008</td>
<td>4.1</td>
<td>45, male</td>
<td>37</td>
<td>NA</td>
<td>12</td>
<td>74/14</td>
<td>Yes</td>
<td>Paternal</td>
<td>19</td>
<td>17</td>
<td>13</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>SCA-009</td>
<td>4.2</td>
<td>75, male</td>
<td>60</td>
<td>NA</td>
<td>17</td>
<td>67/14</td>
<td>Yes</td>
<td>Paternal</td>
<td>19</td>
<td>17</td>
<td>13</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>SCA-010</td>
<td>5.1</td>
<td>80, male</td>
<td>45</td>
<td>NA</td>
<td>24</td>
<td>68/22</td>
<td>Yes</td>
<td>Paternal</td>
<td>19</td>
<td>17</td>
<td>13</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>SCA-011</td>
<td>5.2</td>
<td>45, male</td>
<td>46</td>
<td>NA</td>
<td>10</td>
<td>89/22</td>
<td>Yes</td>
<td>Paternal</td>
<td>19</td>
<td>17</td>
<td>13</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>SCA-012</td>
<td>5.3</td>
<td>61, male</td>
<td>81</td>
<td>NA</td>
<td>3</td>
<td>89/15</td>
<td>Yes</td>
<td>Paternal</td>
<td>19</td>
<td>17</td>
<td>13</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>SCA-013</td>
<td>5.4</td>
<td>40, male</td>
<td>35</td>
<td>NA</td>
<td>8</td>
<td>75/23</td>
<td>Yes</td>
<td>Paternal</td>
<td>19</td>
<td>17</td>
<td>13</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

NA: not available

ATXN3 allelic distribution

A total of 682 alleles from 341 ataxic patients were identified by PCR and TP-PCR (Figure 3). We identified 18 pathogenic alleles ranging from 61 to 75 CAG repeats (2.6%). The remaining 664 normal ATXN3 alleles ranged from 12 to 38 CAG repeats, with the 23-repeat allele the most common (32.1%) followed by 14-repeat allele (26%). Moreover, we found 101 LN alleles counting for about 14.8% of the total of alleles.

Discussion

Our findings suggest that MJD/SCA3 is rare in the Peruvian population, with a predominantly foreign origin. We found 18 MJD/SCA3 cases from seven different families, with a relative frequency of 5% of all ataxic cases with clinical diagnosis of inherited ataxia registered from January 1996 to February 2022 in our center. A previous study in Peru reported SCA10 as the most common hereditary ataxia and found just three MJD/SCA3 cases [22]. Based on the extended pedigrees we identified that almost all MJD/SCA3 cases have a foreign origin (Figure 3; Figure S2-S6). Two families reported that all affected older individuals were Peruvian, but we could not reject an external origin in these families (Fig.3; Figures S1 & S7). This frequency contrasts with the reports from Brazil (59.6%); however, is consistent with other Latin American countries, such as Mexico (12%) [14] and Cuba (1.2%) [15]. It should be noted that the remaining countries -Argentina, Chile, Venezuela- have a low sample size (n<120), which could increase the actual MJD/SCA3 frequency. Brazil is the country with the highest MJD/SCA3 due to its ancestry from Azorean island families and their founder effect for MJD/SCA3 in South Brazil [23]. Nevertheless,
SCA10 predominates in Latin American countries due to Amerindian ancestry, whereas MJD/SCA3 has a low frequency and restricts additional comparison between populations.

MJD/SCA3 in Peru may have been linked to waves of immigrations waves from Europe and Asia. This phenomenon is considered a powerful force shaping the social organization, evolution, and genetics of populations [24]. Therefore, immigrants can pass on their genes to offspring along with their traits and even diseases such as MJD/SCA3. At least five out of seven families traced an affected family member coming from England, China, Japan, and Trinidad and Tobago (Fig.3). During the late 1800s and early 1900s a considerable number of British emigrants settled in Peru due to the foundation of the European Immigration Society [25]. British immigrants settled mainly in the Coast, establishing villages across the country. On the other hand, thousands of male Asian coolies, mainly Chinese, came to Peru during the XIX Century as a cheap labor force, to work on agriculture, guano islands and railway construction [26]. Due to exploitation and semi-slavery, Chinese workers began rebellions in different estates in the 1870s, hence landowners preferred to abandon the use of Chinese workers, decreasing the labor force. At the same time, Japanese immigration started as an agreement between the government of Japan and Peru, since Japan was experiencing a demographic crisis, while Peru needed labor for work on agriculture [27]. There is no significant historical information regarding immigration from Trinidad y Tobago to Peru. It should be considered a possibility that affected ancient ancestors might be related among some identified families, especially if they live in the same region.

The clinical features of MJD/SCA3 Peruvian patients were concordant with previous reports [3;4]. The mean age at onset (46.3 ± 13.3 yr) was slightly older than usual (34-40 yrs) [20]. The diagnostic delay of 15.6 years represents up to three times the diagnostic delay of 5 years recently reported in a Brazilian cohort presumably associated with limited access to genetic testing in Peru being almost exclusively available in the capital city. Neurological examination confirmed cerebellar ataxia as the main and predominant symptom in all patients, accompanied by other frequent symptoms such as dysarthria (94.1%), abnormal eye movements (88.2%) and peripheral neuropathy (70-76.5%). Abnormal eye movements include mainly nystagmus, upward gaze palsy (UGP), slow and dysmetric saccades and saccadic intrusions and “bulging eyes”. UGP, found in 64% of cases, has been proposed as an orienting sign that might distinguish MJD/SCA3 from other SCAs [28;29]. By contrast, spasticity (12.5%), dystonia (5.9%) and chorea (5.9%) were uncommon symptoms in our cohort compared to others [20]; however, their frequency might be affected by the small sample size collected. Dystonia was detected in only one patient and no cases with parkinsonism were found. Non-motor symptoms such as sensory disturbances (94.1%) and depression (75%) were consistent with other MJD/SCA3 reports [30;31]. Despite cognitive impairment being suggested by the MoCA score of some MJD/SCA3 patients, none of them underwent a neuropsychology assessment. The phenotypic variation within families was not clearly observed, due to limited affected family members per family; however, the family SCA3-003 reflects a variable phenotypic expression ranging from mild ataxia to severe and disabling ataxic syndrome with spasticity.

Although PCR followed by capillary electrophoresis is the gold standard to genotype ATXN3 gene due its accuracy to measure alleles, we have been able to determine the length of normal and pathogenic alleles
based on reference samples that have been genotyped previously by this method. Only 18 pathogenic alleles from 61 to 75 CAG repeats were identified (2.6%) of the total of 682 genotyped alleles. The allelic distribution also showed the 23-repeat CAG allele as the most frequent (32.1%) followed by the 14-repeat CAG allele (26%). Normal alleles ranged from 12 to 38 repeats, which is similar to Caucasian [32;33], Asian [21;34], and Latin American [14] populations. We also found that 14.8% of the total of alleles corresponded to the LN subgroup, which were carried by MJD/SCA3 patients and non-MJD/SCA3 patients. This result is consistent with a previous report in Peru [35], and reinforces the lack of correlation between the frequency of LN alleles and the frequency of clinical MJD/SCA3 originally suggested previously in the literature [21].

Conclusion Or Summary

In conclusion, MJD/SCA3 is very rare in Peru. Almost all affected families have a mutation origin coming from abroad, which suggests this was due to an ancestor’s migration. Patients with MJD/SCA3 manifested the common phenotype reported in the literature. ATXN3 allelic distribution in patients with non-MJD/SCA3 ataxia is similar to the distribution in normal individuals around the world, whereas LN allele frequency reinforces no correlation with the frequency of MJD/SCA3. Longitudinal studies should be performed in order to assess the evolution of the phenotype across the time and haplotypes studies are required to confirm the foreign origin of MJD/SCA3 in the Peruvian cohort.

Declarations

Acknowledgements

We are grateful to Victoria Marca-Ysabel and Diego Veliz-Otani for logistic support and lab assistance, Melissa Moleros for her assistance on recruitment of participants; and Lucy Stirland for her review of the manuscript. We are grateful to the DNA-Neurogenetics Bank of the Instituto Nacional de Ciencias Neurológicas for supporting the collection of DNA samples and associated data used in this publication. Samples from the DNA-Neurogenetics Bank were obtained through informed consent and IRB approval. The content in this publication does not reflect the opinion of the DNA-Neurogenetics Bank.

Ethical Approval

The study was approved by the Ethics Committee at INCN, called the ‘Comité Institucional de Ética en Investigación del Instituto Nacional de Ciencias Neurológicas,’ IRB number 486-2018-CIEI-INCN. All patients provided written informed consent for use of their genetic and clinical data for anonymized research studies at the time of their genetic testing. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.

Competing interests

The authors declare have no conflicts of interest to report.
Authors’s contributions

All authors read and approved the final manuscript. All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Lesly Solis-Ponce, Elison Sarapura-Castro, Karina Milla-Neyra, Maryenela Illanes-Manrique, Pilar Mazzetti, Ismael Araujo-Aliaga, Olimpio Ortega, Maria Luiza Saraiva-Pereira, Laura B. Jardim and Mario Cornejo-Olivas. The first draft of the manuscript was written by Ismael Araujo-Aliaga, Lesly Solis-Ponce and Mario Cornejo-Olivas, and all authors commented on previous versions of the manuscript. All authors read and approved the final version of the manuscript.

Funding

This study was funded by the Peruvian Institution PROCIENCIA-CONCYTEC within the framework of the convention of Research Projects in Health EU-LAC (Contract No. 098-2017-FONDECYT). Authors affiliated to Instituto National de Ciencias Neurológicas are also partially supported by Contract No. 148-2020-PROCIENCIA.

Availability of data and materials

The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.

References


Figures
Figure 1

MJD/SCA3 families in Peru by geographical distribution and origin of ancillary affected family member.

Figure 2

Frequency of Clinical Findings in MJD/SCA3 Peruvian patients.
**Figure 3**

ATXN3 allelic distribution.

Blue and green bars: Normal alleles; Green bars: Large normal alleles; Orange bars: Pathogenic alleles.
Mean: 22.1 CAG. Median: 23 CAG. Mode: 23 CAG

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- TableS1.xlsx
- PedigreesS2.docx